Last update July 17, 2023
Likely Compatibility
We do not have alternatives for Tecovirimat.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Tecovirimat in other languages or writings:
Variable | Value | Unit |
---|---|---|
Molecular weight | 376 | daltons |
Protein Binding | 77 - 82 | % |
VD | 5.5 - 14.7 | l/Kg |
pKa | 9.15 | - |
Tmax | 6 | hours |
T½ | 19 - 21 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Tecovirimat is an antiviral that inhibits the orthopoxvirus VP37 coat protein. It can be used to treat smallpox (in case of an outbreak), monkeypox, and cowpox, and to treat complications due to vaccinia virus replication after smallpox vaccination. Oral administration in 2 daily doses.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its very wide volume of distribution make it highly unlikely that significant quantities will pass into breast milk.
Its side effects are rare and mild. (Siga 2021 y 2020)
Authorized use from 3 kg of weight (DrugBank acces Jul 2023). A 28-month-old boy was treated for 14 days with this drug without side effects. (Vora 2008 )
In severe cases, administration of tecovirimat during lactation should be considered. (CDC 2023)
See below the information of this related product: